Ramat Gan, Israel — March 4, 2026 — Leads & Copy — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.
The clinical-stage biotechnology company reported that the study met its primary endpoint, demonstrating that namodenoson was well tolerated in the patient population. No new safety signals were identified, and the safety profile was consistent with prior clinical experience of namodenoson in other oncological diseases.
The study enrolled 20 patients with advanced PDAC who had received one or more prior lines of therapy. Patients represented a high-risk population, including individuals with varying performance status and advanced metastatic disease.
Secondary endpoints included overall survival (OS) and progression-free survival (PFS). Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings.
According to Prof. Salomon Stemmer, a key opinion leader at the Davidoff Center, Rabin Medical Center, Israel, the favorable safety profile supports continued clinical evaluation of namodenoson. Stemmer added that the company is continuing to monitor survival outcomes as data mature.
Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The drug is also being evaluated in clinical trials for advanced liver cancer.
Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.
Source: Can-Fite BioPharma Ltd.
